PHAYM055: Pharmacology 1 (Masters Level): Pharmacology and CNS disorders

View Online

Atwood, B. K., Straiker, A., & Mackie, K. (2012). CB2: Therapeutic target-in-waiting. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 38(1), 16–20. https://doi.org/10.1016/j.pnpbp.2011.12.001

Balon, R. (2006). Mood, anxiety, and physical illness: body and mind, or mind and body? Depression and Anxiety, 23(6), 377–387. https://doi.org/10.1002/da.20217

Brisbare-Roch, C. (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. 13(2), 150–155. http://www.nature.com.libproxy.ucl.ac.uk/nm/journal/v13/n2/pdf/nm1544.pdf

Carlos H. Schenck, M. W. M. (2005). Insights from studying human sleep disorders. 437 (7063), 1279–1285. http://www.nature.com.libproxy.ucl.ac.uk/nature/journal/v437/n7063/pdf/nature04287.pdf

Carvalho, A. F., & Van Bockstaele, E. J. (2012). Cannabinoid modulation of noradrenergic circuits: Implications for psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 38(1), 59–67. https://doi.org/10.1016/j.pnpbp.2012.01.008

Cera, N., Tartaro, A., & Sensi, S. L. (2014). Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study. PLoS ONE, 9(9). https://doi.org/10.1371/journal.pone.0107145

Cryan, J. F., & Kaupmann, K. (2005). Don't worry 'B' happy!: a role for GABAB receptors in anxiety and depression. Trends in Pharmacological Sciences, 26(1), 36–43. https://doi.org/10.1016/j.tips.2004.11.004

Eric J. Olson, K. R. (2013). Management of common sleep disorders. 88(4), 231–238. http://www.aafp.org/afp/2013/0815/p231.pdf

Freund, T. F. (2003). Interneuron Diversity series: Rhythm and mood in perisomatic inhibition. Trends in Neurosciences, 26(9), 489–495. https://doi.org/10.1016/S0166-2236(03)00227-3

H. Attarian, O. A. (n.d.). Treatment of disorders of hypersomnolence. 16(9), 302–302. http://download.springer.com/static/pdf/61/art%253A10.1007%252Fs11940-014-0302-9.pdf?auth66=1414068132_049751e80fe3aa485ba574ca1df01580&ext=.pdf

Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012). Phytocannabinoids as

novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics, 133(1), 79–97. https://doi.org/10.1016/j.pharmthera.2011.09.002

Holmes, A., Heilig, M., Rupniak, N. M. J., Steckler, T., & Griebel, G. (2003). Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends in Pharmacological Sciences, 24(11), 580–588. https://doi.org/10.1016/j.tips.2003.09.011

Hoyer, D., & Jacobson, L. H. (2013). Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides, 47(6), 477–488. https://doi.org/10.1016/j.npep.2013.10.009

Kalueff, A. V., & Nutt, D. J. (2007). Role of GABA in anxiety and depression. Depression and Anxiety, 24(7), 495–517. https://doi.org/10.1002/da.20262

Kilduff, T. S., & Peyron, C. (2000). The hypocretin/orexin ligand–receptor system: implications for sleep and sleep disorders. Trends in Neurosciences, 23(8), 359–365. https://doi.org/10.1016/S0166-2236(00)01594-0

Levine, J., Cole, D. P., Chengappa, K. N. R., & M.D., S. G. (2001). Anxiety disorders and major depression, together or apart. Depression and Anxiety, 14(2), 94–104. https://doi.org/10.1002/da.1051

Luscher, B., Shen, Q., & Sahir, N. (2011). The GABAergic deficit hypothesis of major depressive disorder. Molecular Psychiatry, 16(4), 383–406. https://doi.org/10.1038/mp.2010.120

Mahowald, M. W., & Schenck, C. H. (1992). Dissociated states of wakefulness and sleep. Neurology, 42 Suppl. 6, 44–52. http://ovidsp.uk.ovid.com/sp-3.29.1a/ovidweb.cgi?QS2=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

Mark W. Mahowald MD. (2007). Pathophysiologic mechanisms in REM sleep behavior

disorder. Current Neurology and Neuroscience Reports, 7(Issue 2), 167–172. https://doi.org/10.1007/s11910-007-0013-7

N.P. Robertson, K. J. P. (2014). Narcolepsy: environment, genes and treatment. 261(8), 1644–1646. http://link.springer.com.libproxy.ucl.ac.uk/article/10.1007/s00415-014-7435-3/fulltext.html

Saper, C. B., & Scammell, T. E. (2013). Emerging therapeutics in sleep. Annals of Neurology, 74(3), 435–440. https://doi.org/10.1002/ana.24000

Smith, K. S., & Rudolph, U. (2012). Anxiety and depression: Mouse genetics and pharmacological approaches to the role of GABAA receptor subtypes. Neuropharmacology, 62(1), 54–62. https://doi.org/10.1016/j.neuropharm.2011.07.026

Sodium oxybate: a primer for pharmacists in the treatment of narcolepsy. (n.d.). https://www.researchgate.net/profile/Kimberley_Begley2/publication/265473606_Sodium_Oxybate_A_Primer_for_Pharmacists_in_the_Treatment_of_Narcolepsy/links/54dceb110cf25b09b912dd40.pdf

Stores, G. (2003). Medication for sleep-wake disorders. Archives of Disease in Childhood, 88(10), 899–903. https://doi.org/10.1136/adc.88.10.899

Strange, P. G. (1992). Brain biochemistry and brain disorders. Oxford University Press.